Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.
GeneDx Holdings Corp. (Nasdaq: WGS), commonly referred to as GeneDx, regularly issues news focused on rare disease genomics, clinical impact, and corporate developments. The company describes itself as the global leader in rare disease diagnosis and a pioneer in genomic medicine, emphasizing the role of exome and genome sequencing and its GeneDx Infinity dataset in transforming care.
News updates from GeneDx often highlight financial results and guidance, including revenue trends, exome and genome test volumes, and margin profiles, alongside commentary on how these metrics relate to the company’s growth in genomic testing. Earnings releases may be accompanied by details on conference calls and investor presentations.
GeneDx also publishes frequent announcements on scientific and clinical milestones. These include peer‑reviewed publications, participation in large genomic newborn screening programs such as GUARDIAN and BEACONS, and recognition of its research by major medical journals. The company’s news flow covers conference presentations, advances in rapid genome sequencing, and developments in long‑read sequencing and gene–disease discovery.
Additional news items describe new test offerings like GenomeDx Prenatal, leadership appointments in medical and business roles, and partnerships such as the collaboration with Komodo Health to link GeneDx Infinity with real‑world healthcare data. For readers following WGS, this news page provides a centralized view of GeneDx’s financial disclosures, research output, clinical initiatives, and strategic collaborations in rare disease genomics.
GeneDx (Nasdaq: WGS) reported Q1 2026 revenue of $102.3M and exome/genome revenue $90.6M, with test volume of 27,488 (up 34% YoY). Adjusted gross margin was 69% and adjusted net loss was $8.2M. Cash and equivalents totaled $171.7M as of March 31, 2026.
The company updated full‑year 2026 guidance to $475–$490M revenue, at least 30% exome/genome volume growth, ~70% adjusted gross margin, and remains positive on adjusted net income for the year.
GeneDx (Nasdaq: WGS) will report first quarter 2026 financial results after market close on Monday, May 4, 2026. Management will host a conference call the same day at 4:30 p.m. Eastern Time to discuss financial and operating results.
Investors must register online to access the live call; a live and archived webcast will be available in the Events section of the GeneDx investor relations website.
GeneDx (Nasdaq: WGS) announced SAVES-Kids real-world HEOR findings showing up to 61% reduction in 12-month total healthcare costs for children with epilepsy after ExomeDx and GenomeDx testing, with average costs falling from $130,048 to $50,798 PPPY and average savings of ~$79,250.
The study reports broad cost reductions and fewer hospitalizations and ER visits across epilepsy and DD/ID cohorts, larger gains in Medicaid populations, and shifts toward increased outpatient and pharmacy use consistent with targeted care.
GeneDx (Nasdaq: WGS) and Zevra Therapeutics announced a Sponsored Genetic Testing Program to expand access to GeneDx’s ExomeDx test for U.S. patients with suspected Niemann-Pick disease type C (NPC). Eligible patients may receive testing at no charge, with results available in as little as three weeks.
De-identified data from the program will be added to GeneDx Infinity™, aiming to improve NPC diagnosis speed and support clinical decision-making as new therapies emerge. Zevra will provide financial support for the program.
GeneDx (Nasdaq: WGS) will present 18 abstracts at ACMG 2026 (March 12–13), highlighting sequencing innovations, AI-supported interpretation, and real-world impacts of earlier genomic diagnosis.
Presentations showcase GeneDx Infinity (more than a million exomes and genomes), AI tools to speed variant interpretation, a 51.4% diagnostic yield from >300,000 cases, and benchmarking of advanced sequencing methods.
GeneDx (Nasdaq: WGS) said company management will present at two investor conferences in March 2026: a fireside chat at TD Cowen on March 2, 2026 at 1:50 p.m. ET and a presentation at Barclays on March 11, 2026 at 3:00 p.m. ET.
Live and archived webcasts will be available in the Events section of the GeneDx investor relations website.
GeneDx (Nasdaq: WGS) reported Q4 2025 revenue of $121.0M (27% YoY; 37% ex-adjustment) and full-year 2025 revenue of $427.5M (41% YoY). Exome/genome revenue grew 32% in Q4 to $104.0M; volume rose 34% in Q4 to 27,761 results.
Adjusted gross margin was 71% in Q4 and full-year 2025. Adjusted net income was $4.4M in Q4 and $41.8M for FY2025. GeneDx reaffirmed 2026 guidance: $540–$555M revenue and 33–35% exome/genome growth.
Summary not available.
GeneDx (Nasdaq: WGS) announced that CEO Katherine Stueland was named to the TIME100 Health 2026 list, highlighting GeneDx’s role in rare disease genomics and precision medicine.
Key milestones cited include FDA Breakthrough Device designation for exome/genome testing, AAP guidance updating exome/genome as a first-tier test, and a 3.7% newborn screen positive rate in the GUARDIAN study.
GeneDx (Nasdaq: WGS) will release fourth-quarter 2025 financial results before market open on Monday, February 23, 2026.
Management will host a conference call at 8:30 a.m. Eastern Time that day to discuss financial and operating results. Registration is required; a live and archived webcast will be available on the GeneDx investor relations "Events" page.